share_log

HC Wainwright & Co. Reiterates Buy on Viridian Therapeutics, Maintains $34 Price Target

Benzinga ·  Dec 16, 2024 07:32  · Ratings

HC Wainwright & Co. analyst Douglas Tsao reiterates Viridian Therapeutics (NASDAQ:VRDN) with a Buy and maintains $34 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment